OOIR: Observatory of International Research

Papers

(The H4-Index of Cancer Biology & Medicine is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Eliminating cervical cancer: a global health imperative for women	222
Drugging the ‘undruggable’ KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer	128
Artificial intelligence in breast cancer: applications and advancements	82
Lactate drives immune resistance via a pharmaceutically reversible H3K18la-KIF20A-c-Myc-PD-L1 axis in hepatocellular carcinoma	66
A foundation model-enhanced CT radiomics signature for the noninvasive assessment of tertiary lymphoid structures and prediction of therapy benefit in gastric cancer	55
Early-onset gastric cancer global burden profile, trends, and contributors	54
Unraveling vascular mechanisms in melanoma: roles of angiogenesis and vasculogenic mimicry in tumor progression and therapeutic resistance	53
Immunotherapy rechallenge of patients with advanced NSCLC progression after sequential treatment with third-generation EGFR-TKI and immunotherapy	51
The Warburg effect drives dedifferentiation through epigenetic reprogramming	47
Phase I study of chlorogenic acid injection for recurrent high-grade glioma with long-term follow-up	46
Mitochondrial transplantation sensitizes chemotherapy to inhibit tumor development by enhancing anti-tumor immunity	44
Click chemistry-driven tumor theranostics: recent advances, challenges, and future perspectives	42
Role of the tumor microenvironment in shaping IDH-wildtype glioma plasticity, and potential therapeutic strategies	37
Cancer stem cells: a target for overcoming therapeutic resistance and relapse	35
Stability and variability of molecular subtypes: comparative analysis of primary and metastatic triple-negative breast cancer	35
Cancer-derived exosomal circTMEM56 enhances the efficacy of HCC radiotherapy through the miR-136-5p/STING axis	33
PD-1 inhibitors provide new opportunities in conversion therapy for stage IV gastric cancer	31
Tumor-resident bacteria in gastrointestinal cancers: from regulatory mechanisms to clinical implications	31
Associations between polymorphisms in leptin and leptin receptor genes and colorectal cancer survival	31
Immune checkpoint inhibitors: breakthroughs in cancer treatment	29
The role of radiomics in predicting the response to neoadjuvant chemotherapy for breast cancer	28
Chinese expert consensus on additional surgery following endoscopic resection for early colorectal cancer (2025 edition)	27
Biological mechanism and immune response of MHC-II expression in tumor cells	27
Lung cancer mortality trends in China from 2013 to 2021 and projections to 2030	26
Optimizing the cancer research landscape for the benefit of patients and society: A strategic perspective of the German Cancer Research Center (DKFZ) and its partnerships with university medical cente	25

Chinese Society of Clinical Oncology Non-small Cell Lung Cancer (CSCO NSCLC) guidelines in 2024: key update on the management of early and locally advanced NSCLC